Tags: Drug.
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1 an important regulator of overall eosinophil function.It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT it was to be used to treat severe allergic disorders.In January 2007 CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc.